Takahiro Kinoshita, surgeon, National Cancer Center Hospital East, Tokyo, Japan

Biography

Dr. Kinoshita received his MD in 1994 and PhD in 1999 from Kanazawa University in Japan. From the very first point of his clinical career, he had already believed that the less invasive surgery must be one of the most important surgical skills for him to obtain for cancer treatment, and that idea led him to study under the supervision of renowned surgeon, Dr. Gerhard Buess in the Division of Minimal Invasive Surgery, Department of General Surgery, Eberhard-Karls University of Tuebingen (Germany) in 2001-2003.

Since then, Dr. Kinoshita has focused on the minimal invasive gastric/esophagogastric junction cancer surgery, and now his experiences are more extended to not only laparoscopic surgery (since 2003) but also robotic surgery (since 2014). His experiences reached around 2500 laparoscopic and 600 robotic surgeries.

As his academic achievements and experiences, he has published more than 180 peer-reviewed articles, conducted and attended multi-institutional clinical trials, demonstrated more than twenty live surgeries in many countries (China, Vietnam, Russia, India, and Korea). Furthermore, he is currently in the editorial board of Gastric Cancer, and editorial committee of Japanese Gastric Cancer Treatment Guidelines, the board of directors of JGCA (Japan Gastric Cancer Association), and the senior member of UGIRA (Upper GI International Robotic Association). He is one of the core members of JCOG (Japan Clinical Oncology Group), and the primary investigator of JCOG1809 study. He also focuses on education of the young doctors and has trained both domestic and oversea doctors as the chairman of educational committee of JGCA.

Summary of presentation

In Japan, various domestic clinical trials are underway in response to the changing disease trends in gastric cancer. As for surgery, a randomized p-III trial of laparoscopic surgery vs. robotic surgery for cStage I-III patients (JCOG1907), a p-II trial of laparoscopic/robotic spleen-sparing splenectomy for upper advanced gastric cancer with greater curvature invasion (JCOG1809) are in progress. A p-III trial (JCOG1711) is ongoing to evaluate the non-inferiority of omentum-preserving to omental resection for cT3/4 gastric cancer. In Japan, the standard treatment for locally advanced gastric cancer is basically surgery preceded followed by postoperative adjuvant chemotherapy. Two randomized controlled trials are ongoing to evaluate the efficacy of perioperative chemotherapy including neoadjuvant chemotherapy: JCOG1509 (SOX) and JCOG2203 (DOS/FLOT, targeting EGJ cancer). A p-II trial is ongoing to evaluate the efficacy of preoperative chemotherapy (DOS/FLOT) for large type 3 and 4 carcinoma which have high risk of recurrence. A randomized p-III trial, Phoenix-GC2, is ongoing to evaluate the efficacy of postoperative intraperitoneal paclitaxel administration for the prevention of recurrent peritoneal dissemination in type 4 gastric cancer. In addition, p-II trials of perioperative therapy with ICIs or molecular targeted agents are ongoing: EPOC2001 (FLOT+Pembro+Lenvatinib) and EPOC2003 (TDXd+Capecitabine+Durvalumab). A randomized p-III trial (JCOG2301) is ongoing to evaluate the benefit of conversion surgery in patients with unresectable gastric cancer after successful medical therapy. TR studies are also ongoing, including a whole genome analysis (JCOG2203A1) and the MONSTAR-3 study, in which MRD analysis using a highly sensitive ctDNA detection system and spatial transcriptome analysis were performed. Clinical trials for elderly patients with gastric cancer, which has been increasing in recent years, have also been designed and conducted (JCOG1507, JCOG1902).

 

  • Parallel session 1, Parallel session 2, Parallel session 3

    Current trials in Japan

    Date: 08 May 2025Time: 08:30 - 08:45 CET